Intranasal Vaccine

  • IASbaba
  • July 30, 2021
  • 0
UPSC Articles
Print Friendly, PDF & Email

Intranasal Vaccine

Part of: GS Prelims and GS – II – Health

In news: In another two to two-and-a-half months, Bharat Biotech is going to have significant data on its intranasal COVID-19 vaccine whose clinical trials are under way.

  • New vaccine being developed by Hyderabad based Bharat Biotech is BBV154 – A novel adenovirus vectored, intranasal vaccine for COVID-19
  • Intranasal vaccine is a vaccine administered to a person via the nose and does not require a needle.

Source: Bharat Biotech

What are the benefits of intranasal vaccine?

  • It promises to be more effective, since it is expected to generate immune responses at the site of infection (respiratory mucosa)
  • Non-invasive, Needle-free.
  •  Ease of administration – does not require trained health care workers.
  •  Elimination of needle-associated risks (injuries and infections).
  •  High compliance (Ideally suits for children’s and adults).
  •  Scalable manufacturing – able to meet global demand. It can produce 100 million doses a month.

Also Read: Approaches to vaccine making

News Source: TH

For a dedicated peer group, Motivation & Quick updates, Join our official telegram channel – https://t.me/IASbabaOfficialAccount

Subscribe to our YouTube Channel HERE to watch Explainer Videos, Strategy Sessions, Toppers Talks & many more…

Search now.....

Sign Up To Receive Regular Updates